Results 161 to 170 of about 30,146 (272)
Statement from the frontal fibrosing alopecia international expert alliance: SOFFIA 2024
Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 2, Page 210-223, February 2026.Optimal treatment for frontal fibrosing alopecia (FFA) remains contentious. An international expert panel agreed that highly/ultra‐potent topical steroids were the preferred first‐line topical therapy. Preferred systemic therapies were 5‐alpha reductase inhibitors, followed by hydroxychloroquine.Nekma Meah, Jane Li, Dmitri Wall, Katherine York, Bevin Bhoyrul, Laita Bokhari, Lachlan Coulthard, Leila Asfour, Leonardo Spagnol Abraham, Daniel Asz‐Sigall, Wilma F. Bergfeld, Regina C. Betz, Ulrike Blume‐Peytavi, Valerie Callender, Vijaya Chitreddy, Andrea Combalia, George Cotsarelis, Brittany Craiglow, Rachita Dhurat, Ncoza Dlova, Jeff Donovan, Andrei Doroshkevich, Samantha Eisman, Paul Farrant, Aida Gadzhigoroeva, Jack Green, Ramon Grimalt, Matthew Harries, Maria Hordinsky, Alan D. Irvine, Victoria Jolliffe, Spartak Kaiumov, Brett King, Steven Kossard, Joyce Lee, Won‐Soo Lee, Nino Lortkipanidze, Amy McMichael, Natasha Atanaskova Mesinkovska, Andrew Messenger, Paradi Mirmirani, Elise Olsen, Seth J. Orlow, Yuliya Ovcharenko, Bianca Maria Piraccini, Rodrigo Pirmez, Adriana Rakowska, Pascal Reygagne, Janet Roberts, Lidia Rudnicka, David Saceda‐Corralo, Jerry Shapiro, Pooja Sharma, Tatiana Silyuk, Poonkiat Suchonwanit, Anita Takwale, Antonella Tosti, W. I. Visser, Sergio Vañó‐Galván, Annika Vogt, Martin Wade, Leona Yip, Abraham Zlotogorski, Cheng Zhou, Rodney Sinclair +64 morewiley +1 more sourceWhich patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations [PDF]
, 2016 Barbui, T, Barosi, G, Birgegård, G, Cervantes, F, Griesshammer, M, Harrison, C., Hehlmann, R, Kiladjian, J-J, Kröger, N, Marchetti, M, McMullin, M F, Passamonti, F, Vannucchi, A +12 morecore +1 more sourceJanus kinase and calcineurin‐inhibitor combination in anti‐MDA5 dermatomyositis: No significant survival benefit but reassuring safety profile
Journal of Internal Medicine, Volume 299, Issue 2, Page 228-240, February 2026.Abstract Objectives
Anti‐MDA5 dermatomyositis (anti‐MDA5 DM) is the most severe subtype of dermatomyositis, due to its pulmonary involvement. Current treatment involves corticosteroids and immunosuppressants, but variability in responses exists. This study aims to evaluate the efficacy and safety of Janus kinase (JAK)– and calcineurin–inhibitor ...Valentine Pagis, Quentin Astouati, Lucas Pacoureau, Yann Nguyen, Pierre Bay, Antoine Roux, Laure Gallay, Vincent Cottin, Benjamin Terrier, Alain Meyer, Charles Cerf, Mathilde Neuville, Baptiste Hervier, Arthur Renaud, Benoit Suzon, Nicolas Schleinitz, Thomas Papo, Pascaline Priou, Arsène Mekinian, Audrey Ullmer, Erwan Oehler, Noémie Gensous, Alice Berezne, Luc De Saint Martin, Thierry Marhadour, Mickaël Martin, Amélie Servettaz, Maxime Samson, Laurent Gilardin, Pierre Charles, Juliette Woessner, Thierry Carmoi, Baptiste Dilly, Wladimir Mauhin, Nicolas Baillet, Sébastien Humbert, Benjamin Thoreau, Marine Lemaitre, Claire Le Pendu, Pierre Loiseau, Thomas Quemeneur, Elodie Blanchard, Nicol Voermans, David Launay, Hilario Nunes, Olivier Benveniste, Yurdagul Uzunhan, Yves Allenbach +47 morewiley +1 more sourceThe combination of ruxolitinib and the CDK4/6 inhibitor abemaciclib demonstrates safety and efficacy in previously treated myelofibrosis patients: Results of A phase I study [PDF]
Jan Philipp Bewersdorf, Andriy Derkach, Amer M. Zeidan, Emily Burton, K. Kan, M.E. Giuliani, Jeetayu Biswas, Michael J. Mauro, Brian Chernak, Tamanna Haque, Nikolai A. Podoltsev, Ross L. Levine, Prithviraj Bose, Raajit K. Rampal +13 moreopenalex +1 more sourceTherapeutic targeting of chromatin alterations in leukemia and solid tumors
International Journal of Cancer, Volume 158, Issue 2, Page 382-408, 15 January 2026.Abstract
Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert +7 morewiley +1 more sourcePF658 THE NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) IS A CHEAP SURROGATE OF EXPANSION OF MYELOID‐DERIVED SUPPRESSOR CELLS IN MYELOFIBROSIS BEFORE AND AFTER TREATMENT WITH RUXOLITINIB: A SINGLE‐CENTER EXPERIENCE
, 2019 Antonio Romano, Nunziatina Laura Parrinello, Cesarina Giallongo, Fabrizio Puglisi, Daniela Cambria, Giuseppina Camiolo, Daniele Tibullo, E. Lambusta, Francesco Di Raimondo, Giuseppe A. Palumbo +9 moreopenalex +1 more source
